Pharmaceuticals Roche receives Swiss approval for eye injection
The pharmaceutical company Roche has now also received approval in Switzerland for its eye medication Vabysmo in a prefilled syringe for the treatment of three retinal diseases.
16.12.2024, 07:50
SDA
After the EU Commission gave the green light on Friday, the Swiss Agency for Therapeutic Products (Swissmedic) has now also granted approval.
As Roche wrote on Friday, the single-dose prefilled syringe is currently the only practical alternative to the Vabysmo vials that are otherwise available. It can be used to treat neovascular or "wet" age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). All three can lead to loss of vision if left untreated.
The ready-to-use syringe is packaged together with a specific needle especially for intravitreal injection - i.e. it can be injected into the vitreous body of the eye as it is - and offers ophthalmologists a convenient way to administer this treatment, according to the press release issued on Friday. More than nine million people in the EU are affected by these diseases.
